Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

DSpace Repository

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

Author: McArthur, Grant A.; Chapman, Paul B.; Robert, Caroline; Larkin, James; Haanen, John B.; Dummer, Reinhard; Ribas, Antoni; Hogg, David; Hamid, Omid; Ascierto, Paolo A.; Garbe, Claus; Testori, Alessandro; Maio, Michele; Lorigan, Paul; Lebbe, Celeste; Jouary, Thomas; Schadendorf, Dirk; O'Day, Stephen J.; Kirkwood, John M.; Eggermont, Alexander M.; Dreno, Brigitte; Sosman, Jefferey A.; Flaherty, Keith T.; Yin, Ming; Caro, Ivor; Cheng, Suzanne; Trunzer, Kerstin; Hauschild, Axel
Tübinger Autor(en):
Garbe, Claus
Published in: Lancet Oncology (2014), Bd. 15, H. 3, S. 323-332
Verlagsangabe: Elsevier Science Inc
Language: English
Full text: http://dx.doi.org/10.1016/S1470-2045(14)70012-9
ISSN: 1470-2045
DDC Classifikation: 610 - Medicine and health
Dokumentart: Artikel
Show full item record

This item appears in the following Collection(s)